nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Ezetimibe—atherosclerosis	0.104	0.211	CbGbCtD
Rifaximin—CYP3A4—Rosuvastatin—atherosclerosis	0.104	0.211	CbGbCtD
Rifaximin—CYP3A4—Simvastatin—atherosclerosis	0.0966	0.196	CbGbCtD
Rifaximin—CYP3A4—Pravastatin—atherosclerosis	0.0946	0.192	CbGbCtD
Rifaximin—CYP3A4—Lovastatin—atherosclerosis	0.0946	0.192	CbGbCtD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—CYP7A1—atherosclerosis	0.0136	0.141	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG1—atherosclerosis	0.00865	0.0895	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP7A1—atherosclerosis	0.00784	0.0811	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—atherosclerosis	0.00679	0.0702	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—NPC1—atherosclerosis	0.0049	0.0507	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.00405	0.0419	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—ESR2—atherosclerosis	0.00384	0.0397	CbGpPWpGaD
Rifaximin—CYP3A4—Liver X Receptor Pathway—ABCG8—atherosclerosis	0.00337	0.0348	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR2—atherosclerosis	0.00303	0.0314	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.00281	0.029	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—PPARA—atherosclerosis	0.00257	0.0266	CbGpPWpGaD
Rifaximin—CYP3A4—Liver X Receptor Pathway—CYP7A1—atherosclerosis	0.00241	0.025	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—ESR1—atherosclerosis	0.00233	0.0241	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	0.00232	0.024	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—PPARG—atherosclerosis	0.00212	0.022	CbGpPWpGaD
Rifaximin—CYP3A4—Liver X Receptor Pathway—ABCG5—atherosclerosis	0.00209	0.0216	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARA—atherosclerosis	0.00203	0.021	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR1—atherosclerosis	0.00184	0.019	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARG—atherosclerosis	0.00168	0.0174	CbGpPWpGaD
Rifaximin—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00161	0.00392	CcSEcCtD
Rifaximin—Pharyngitis—Ezetimibe—atherosclerosis	0.00159	0.00389	CcSEcCtD
Rifaximin—Oedema peripheral—Ezetimibe—atherosclerosis	0.00158	0.00386	CcSEcCtD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—CYP7A1—atherosclerosis	0.00158	0.0163	CbGpPWpGaD
Rifaximin—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00158	0.00385	CcSEcCtD
Rifaximin—Weight increased—Pravastatin—atherosclerosis	0.00157	0.00384	CcSEcCtD
Rifaximin—Weight decreased—Pravastatin—atherosclerosis	0.00156	0.00382	CcSEcCtD
Rifaximin—Depression—Pravastatin—atherosclerosis	0.00154	0.00375	CcSEcCtD
Rifaximin—Angioedema—Rosuvastatin—atherosclerosis	0.00154	0.00375	CcSEcCtD
Rifaximin—Flushing—Lovastatin—atherosclerosis	0.00152	0.00371	CcSEcCtD
Rifaximin—Flushing—Ezetimibe—atherosclerosis	0.00149	0.00363	CcSEcCtD
Rifaximin—Cough—Rosuvastatin—atherosclerosis	0.00147	0.00358	CcSEcCtD
Rifaximin—Angiopathy—Ezetimibe—atherosclerosis	0.00146	0.00355	CcSEcCtD
Rifaximin—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00145	0.00353	CcSEcCtD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—CYP7A1—atherosclerosis	0.00144	0.0149	CbGpPWpGaD
Rifaximin—Arthralgia—Rosuvastatin—atherosclerosis	0.00143	0.00349	CcSEcCtD
Rifaximin—Myalgia—Rosuvastatin—atherosclerosis	0.00143	0.00349	CcSEcCtD
Rifaximin—Flushing—Simvastatin—atherosclerosis	0.00142	0.00347	CcSEcCtD
Rifaximin—Haemoglobin—Niacin—atherosclerosis	0.00141	0.00345	CcSEcCtD
Rifaximin—Rhinitis—Niacin—atherosclerosis	0.00141	0.00344	CcSEcCtD
Rifaximin—Mental disorder—Ezetimibe—atherosclerosis	0.00141	0.00343	CcSEcCtD
Rifaximin—Haemorrhage—Niacin—atherosclerosis	0.00141	0.00343	CcSEcCtD
Rifaximin—Flatulence—Lovastatin—atherosclerosis	0.0014	0.00343	CcSEcCtD
Rifaximin—Hypoaesthesia—Niacin—atherosclerosis	0.0014	0.00341	CcSEcCtD
Rifaximin—Malnutrition—Ezetimibe—atherosclerosis	0.0014	0.00341	CcSEcCtD
Rifaximin—Rhinitis—Pravastatin—atherosclerosis	0.00139	0.00339	CcSEcCtD
Rifaximin—Oedema peripheral—Niacin—atherosclerosis	0.00138	0.00338	CcSEcCtD
Rifaximin—Confusional state—Rosuvastatin—atherosclerosis	0.00138	0.00338	CcSEcCtD
Rifaximin—Back pain—Lovastatin—atherosclerosis	0.00138	0.00336	CcSEcCtD
Rifaximin—Hypoaesthesia—Pravastatin—atherosclerosis	0.00138	0.00336	CcSEcCtD
Rifaximin—Flatulence—Ezetimibe—atherosclerosis	0.00138	0.00336	CcSEcCtD
Rifaximin—Pharyngitis—Pravastatin—atherosclerosis	0.00137	0.00335	CcSEcCtD
Rifaximin—Muscle spasms—Lovastatin—atherosclerosis	0.00137	0.00334	CcSEcCtD
Rifaximin—Infection—Rosuvastatin—atherosclerosis	0.00136	0.00333	CcSEcCtD
Rifaximin—Back pain—Ezetimibe—atherosclerosis	0.00135	0.0033	CcSEcCtD
Rifaximin—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00135	0.00328	CcSEcCtD
Rifaximin—Muscle spasms—Ezetimibe—atherosclerosis	0.00134	0.00328	CcSEcCtD
Rifaximin—Mental disorder—Simvastatin—atherosclerosis	0.00134	0.00327	CcSEcCtD
Rifaximin—Tremor—Lovastatin—atherosclerosis	0.00133	0.00326	CcSEcCtD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—atherosclerosis	0.00133	0.0137	CbGpPWpGaD
Rifaximin—Ill-defined disorder—Lovastatin—atherosclerosis	0.00132	0.00323	CcSEcCtD
Rifaximin—Flatulence—Simvastatin—atherosclerosis	0.00131	0.0032	CcSEcCtD
Rifaximin—Tinnitus—Niacin—atherosclerosis	0.00131	0.0032	CcSEcCtD
Rifaximin—Flushing—Niacin—atherosclerosis	0.0013	0.00318	CcSEcCtD
Rifaximin—Angioedema—Lovastatin—atherosclerosis	0.0013	0.00318	CcSEcCtD
Rifaximin—Ill-defined disorder—Ezetimibe—atherosclerosis	0.0013	0.00316	CcSEcCtD
Rifaximin—Anaemia—Ezetimibe—atherosclerosis	0.00129	0.00315	CcSEcCtD
Rifaximin—Tinnitus—Pravastatin—atherosclerosis	0.00129	0.00315	CcSEcCtD
Rifaximin—Malaise—Lovastatin—atherosclerosis	0.00128	0.00313	CcSEcCtD
Rifaximin—Flushing—Pravastatin—atherosclerosis	0.00128	0.00313	CcSEcCtD
Rifaximin—Muscle spasms—Simvastatin—atherosclerosis	0.00128	0.00313	CcSEcCtD
Rifaximin—Vertigo—Lovastatin—atherosclerosis	0.00128	0.00312	CcSEcCtD
Rifaximin—Angioedema—Ezetimibe—atherosclerosis	0.00128	0.00312	CcSEcCtD
Rifaximin—Angiopathy—Niacin—atherosclerosis	0.00127	0.00311	CcSEcCtD
Rifaximin—Malaise—Ezetimibe—atherosclerosis	0.00126	0.00307	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00125	0.00305	CcSEcCtD
Rifaximin—Tremor—Simvastatin—atherosclerosis	0.00125	0.00305	CcSEcCtD
Rifaximin—Insomnia—Rosuvastatin—atherosclerosis	0.00124	0.00303	CcSEcCtD
Rifaximin—Ill-defined disorder—Simvastatin—atherosclerosis	0.00124	0.00302	CcSEcCtD
Rifaximin—Anaemia—Simvastatin—atherosclerosis	0.00123	0.00301	CcSEcCtD
Rifaximin—Malnutrition—Niacin—atherosclerosis	0.00122	0.00299	CcSEcCtD
Rifaximin—Cough—Ezetimibe—atherosclerosis	0.00122	0.00298	CcSEcCtD
Rifaximin—Angioedema—Simvastatin—atherosclerosis	0.00122	0.00297	CcSEcCtD
Rifaximin—Myalgia—Lovastatin—atherosclerosis	0.00121	0.00296	CcSEcCtD
Rifaximin—Arthralgia—Lovastatin—atherosclerosis	0.00121	0.00296	CcSEcCtD
Rifaximin—Chest pain—Lovastatin—atherosclerosis	0.00121	0.00296	CcSEcCtD
Rifaximin—Flatulence—Niacin—atherosclerosis	0.00121	0.00294	CcSEcCtD
Rifaximin—Malaise—Simvastatin—atherosclerosis	0.0012	0.00293	CcSEcCtD
Rifaximin—Discomfort—Lovastatin—atherosclerosis	0.0012	0.00292	CcSEcCtD
Rifaximin—Vertigo—Simvastatin—atherosclerosis	0.0012	0.00292	CcSEcCtD
Rifaximin—Arthralgia—Ezetimibe—atherosclerosis	0.00119	0.0029	CcSEcCtD
Rifaximin—Chest pain—Ezetimibe—atherosclerosis	0.00119	0.0029	CcSEcCtD
Rifaximin—Myalgia—Ezetimibe—atherosclerosis	0.00119	0.0029	CcSEcCtD
Rifaximin—Flatulence—Pravastatin—atherosclerosis	0.00119	0.0029	CcSEcCtD
Rifaximin—Dry mouth—Lovastatin—atherosclerosis	0.00119	0.00289	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00118	0.00288	CcSEcCtD
Rifaximin—Muscle spasms—Niacin—atherosclerosis	0.00118	0.00287	CcSEcCtD
Rifaximin—Discomfort—Ezetimibe—atherosclerosis	0.00118	0.00287	CcSEcCtD
Rifaximin—Constipation—Rosuvastatin—atherosclerosis	0.00117	0.00286	CcSEcCtD
Rifaximin—Pain—Rosuvastatin—atherosclerosis	0.00117	0.00286	CcSEcCtD
Rifaximin—Confusional state—Lovastatin—atherosclerosis	0.00117	0.00286	CcSEcCtD
Rifaximin—Dry mouth—Ezetimibe—atherosclerosis	0.00116	0.00284	CcSEcCtD
Rifaximin—Anaphylactic shock—Lovastatin—atherosclerosis	0.00116	0.00284	CcSEcCtD
Rifaximin—Muscle spasms—Pravastatin—atherosclerosis	0.00116	0.00283	CcSEcCtD
Rifaximin—Infection—Lovastatin—atherosclerosis	0.00115	0.00282	CcSEcCtD
Rifaximin—Confusional state—Ezetimibe—atherosclerosis	0.00115	0.00281	CcSEcCtD
Rifaximin—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00114	0.00278	CcSEcCtD
Rifaximin—Myalgia—Simvastatin—atherosclerosis	0.00113	0.00277	CcSEcCtD
Rifaximin—Chest pain—Simvastatin—atherosclerosis	0.00113	0.00277	CcSEcCtD
Rifaximin—Arthralgia—Simvastatin—atherosclerosis	0.00113	0.00277	CcSEcCtD
Rifaximin—Infection—Ezetimibe—atherosclerosis	0.00113	0.00276	CcSEcCtD
Rifaximin—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00113	0.00276	CcSEcCtD
Rifaximin—Tremor—Pravastatin—atherosclerosis	0.00113	0.00275	CcSEcCtD
Rifaximin—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00112	0.00274	CcSEcCtD
Rifaximin—Discomfort—Simvastatin—atherosclerosis	0.00112	0.00273	CcSEcCtD
Rifaximin—Nervous system disorder—Ezetimibe—atherosclerosis	0.00112	0.00273	CcSEcCtD
Rifaximin—Angioedema—Niacin—atherosclerosis	0.00112	0.00273	CcSEcCtD
Rifaximin—Ill-defined disorder—Pravastatin—atherosclerosis	0.00112	0.00273	CcSEcCtD
Rifaximin—Anaemia—Pravastatin—atherosclerosis	0.00111	0.00272	CcSEcCtD
Rifaximin—Anorexia—Lovastatin—atherosclerosis	0.00111	0.0027	CcSEcCtD
Rifaximin—Skin disorder—Ezetimibe—atherosclerosis	0.00111	0.0027	CcSEcCtD
Rifaximin—Angioedema—Pravastatin—atherosclerosis	0.0011	0.00269	CcSEcCtD
Rifaximin—Vertigo—Niacin—atherosclerosis	0.0011	0.00268	CcSEcCtD
Rifaximin—Syncope—Niacin—atherosclerosis	0.0011	0.00268	CcSEcCtD
Rifaximin—Confusional state—Simvastatin—atherosclerosis	0.0011	0.00268	CcSEcCtD
Rifaximin—Urticaria—Rosuvastatin—atherosclerosis	0.00109	0.00266	CcSEcCtD
Rifaximin—Anaphylactic shock—Simvastatin—atherosclerosis	0.00109	0.00265	CcSEcCtD
Rifaximin—Malaise—Pravastatin—atherosclerosis	0.00109	0.00265	CcSEcCtD
Rifaximin—Abdominal pain—Rosuvastatin—atherosclerosis	0.00108	0.00265	CcSEcCtD
Rifaximin—Vertigo—Pravastatin—atherosclerosis	0.00108	0.00264	CcSEcCtD
Rifaximin—Infection—Simvastatin—atherosclerosis	0.00108	0.00264	CcSEcCtD
Rifaximin—Loss of consciousness—Niacin—atherosclerosis	0.00108	0.00262	CcSEcCtD
Rifaximin—Cough—Niacin—atherosclerosis	0.00107	0.00261	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00106	0.00258	CcSEcCtD
Rifaximin—Insomnia—Lovastatin—atherosclerosis	0.00105	0.00257	CcSEcCtD
Rifaximin—Cough—Pravastatin—atherosclerosis	0.00105	0.00257	CcSEcCtD
Rifaximin—Myalgia—Niacin—atherosclerosis	0.00104	0.00254	CcSEcCtD
Rifaximin—Arthralgia—Niacin—atherosclerosis	0.00104	0.00254	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00104	0.00254	CcSEcCtD
Rifaximin—Anorexia—Simvastatin—atherosclerosis	0.00104	0.00253	CcSEcCtD
Rifaximin—Dyspnoea—Lovastatin—atherosclerosis	0.00104	0.00253	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00103	0.00252	CcSEcCtD
Rifaximin—Insomnia—Ezetimibe—atherosclerosis	0.00103	0.00252	CcSEcCtD
Rifaximin—Chest pain—Pravastatin—atherosclerosis	0.00103	0.0025	CcSEcCtD
Rifaximin—Myalgia—Pravastatin—atherosclerosis	0.00103	0.0025	CcSEcCtD
Rifaximin—Arthralgia—Pravastatin—atherosclerosis	0.00103	0.0025	CcSEcCtD
Rifaximin—Dry mouth—Niacin—atherosclerosis	0.00102	0.00249	CcSEcCtD
Rifaximin—Dyspnoea—Ezetimibe—atherosclerosis	0.00102	0.00248	CcSEcCtD
Rifaximin—Discomfort—Pravastatin—atherosclerosis	0.00101	0.00247	CcSEcCtD
Rifaximin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00101	0.00247	CcSEcCtD
Rifaximin—Decreased appetite—Lovastatin—atherosclerosis	0.00101	0.00247	CcSEcCtD
Rifaximin—Fatigue—Lovastatin—atherosclerosis	0.001	0.00245	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG1—atherosclerosis	0.001	0.0103	CbGpPWpGaD
Rifaximin—Anaphylactic shock—Niacin—atherosclerosis	0.000998	0.00244	CcSEcCtD
Rifaximin—Pain—Lovastatin—atherosclerosis	0.000994	0.00243	CcSEcCtD
Rifaximin—Constipation—Lovastatin—atherosclerosis	0.000994	0.00243	CcSEcCtD
Rifaximin—Confusional state—Pravastatin—atherosclerosis	0.000991	0.00242	CcSEcCtD
Rifaximin—Decreased appetite—Ezetimibe—atherosclerosis	0.000991	0.00242	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000991	0.00242	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000984	0.0024	CcSEcCtD
Rifaximin—Asthenia—Rosuvastatin—atherosclerosis	0.000984	0.0024	CcSEcCtD
Rifaximin—Insomnia—Simvastatin—atherosclerosis	0.000983	0.0024	CcSEcCtD
Rifaximin—Anaphylactic shock—Pravastatin—atherosclerosis	0.000983	0.0024	CcSEcCtD
Rifaximin—Fatigue—Ezetimibe—atherosclerosis	0.000983	0.0024	CcSEcCtD
Rifaximin—Shock—Niacin—atherosclerosis	0.000982	0.0024	CcSEcCtD
Rifaximin—Infection—Pravastatin—atherosclerosis	0.000977	0.00238	CcSEcCtD
Rifaximin—Constipation—Ezetimibe—atherosclerosis	0.000975	0.00238	CcSEcCtD
Rifaximin—Pain—Ezetimibe—atherosclerosis	0.000975	0.00238	CcSEcCtD
Rifaximin—Pruritus—Rosuvastatin—atherosclerosis	0.00097	0.00237	CcSEcCtD
Rifaximin—Skin disorder—Niacin—atherosclerosis	0.00097	0.00237	CcSEcCtD
Rifaximin—Dyspnoea—Simvastatin—atherosclerosis	0.000969	0.00237	CcSEcCtD
Rifaximin—Hyperhidrosis—Niacin—atherosclerosis	0.000965	0.00236	CcSEcCtD
Rifaximin—Feeling abnormal—Lovastatin—atherosclerosis	0.000958	0.00234	CcSEcCtD
Rifaximin—Anorexia—Niacin—atherosclerosis	0.000952	0.00232	CcSEcCtD
Rifaximin—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000951	0.00232	CcSEcCtD
Rifaximin—Hyperhidrosis—Pravastatin—atherosclerosis	0.00095	0.00232	CcSEcCtD
Rifaximin—Decreased appetite—Simvastatin—atherosclerosis	0.000945	0.00231	CcSEcCtD
Rifaximin—Feeling abnormal—Ezetimibe—atherosclerosis	0.00094	0.00229	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000939	0.00229	CcSEcCtD
Rifaximin—Diarrhoea—Rosuvastatin—atherosclerosis	0.000938	0.00229	CcSEcCtD
Rifaximin—Fatigue—Simvastatin—atherosclerosis	0.000937	0.00229	CcSEcCtD
Rifaximin—Anorexia—Pravastatin—atherosclerosis	0.000937	0.00229	CcSEcCtD
Rifaximin—Hypotension—Niacin—atherosclerosis	0.000933	0.00228	CcSEcCtD
Rifaximin—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000932	0.00228	CcSEcCtD
Rifaximin—Constipation—Simvastatin—atherosclerosis	0.00093	0.00227	CcSEcCtD
Rifaximin—Pain—Simvastatin—atherosclerosis	0.00093	0.00227	CcSEcCtD
Rifaximin—Urticaria—Lovastatin—atherosclerosis	0.000923	0.00225	CcSEcCtD
Rifaximin—Body temperature increased—Lovastatin—atherosclerosis	0.000919	0.00224	CcSEcCtD
Rifaximin—Abdominal pain—Lovastatin—atherosclerosis	0.000919	0.00224	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00091	0.00222	CcSEcCtD
Rifaximin—Dizziness—Rosuvastatin—atherosclerosis	0.000907	0.00221	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP7A1—atherosclerosis	0.000907	0.00938	CbGpPWpGaD
Rifaximin—Urticaria—Ezetimibe—atherosclerosis	0.000906	0.00221	CcSEcCtD
Rifaximin—Insomnia—Niacin—atherosclerosis	0.000903	0.0022	CcSEcCtD
Rifaximin—Abdominal pain—Ezetimibe—atherosclerosis	0.000901	0.0022	CcSEcCtD
Rifaximin—Body temperature increased—Ezetimibe—atherosclerosis	0.000901	0.0022	CcSEcCtD
Rifaximin—Feeling abnormal—Simvastatin—atherosclerosis	0.000896	0.00219	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000896	0.00219	CcSEcCtD
Rifaximin—Dyspnoea—Niacin—atherosclerosis	0.00089	0.00217	CcSEcCtD
Rifaximin—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000889	0.00217	CcSEcCtD
Rifaximin—Insomnia—Pravastatin—atherosclerosis	0.000889	0.00217	CcSEcCtD
Rifaximin—Dyspnoea—Pravastatin—atherosclerosis	0.000876	0.00214	CcSEcCtD
Rifaximin—Decreased appetite—Niacin—atherosclerosis	0.000868	0.00212	CcSEcCtD
Rifaximin—Rash—Rosuvastatin—atherosclerosis	0.000865	0.00211	CcSEcCtD
Rifaximin—Dermatitis—Rosuvastatin—atherosclerosis	0.000864	0.00211	CcSEcCtD
Rifaximin—Urticaria—Simvastatin—atherosclerosis	0.000864	0.00211	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Niacin—atherosclerosis	0.000862	0.0021	CcSEcCtD
Rifaximin—Abdominal pain—Simvastatin—atherosclerosis	0.00086	0.0021	CcSEcCtD
Rifaximin—Body temperature increased—Simvastatin—atherosclerosis	0.00086	0.0021	CcSEcCtD
Rifaximin—Headache—Rosuvastatin—atherosclerosis	0.000859	0.0021	CcSEcCtD
Rifaximin—Hypersensitivity—Lovastatin—atherosclerosis	0.000856	0.00209	CcSEcCtD
Rifaximin—Decreased appetite—Pravastatin—atherosclerosis	0.000855	0.00209	CcSEcCtD
Rifaximin—Pain—Niacin—atherosclerosis	0.000854	0.00208	CcSEcCtD
Rifaximin—Fatigue—Pravastatin—atherosclerosis	0.000847	0.00207	CcSEcCtD
Rifaximin—Constipation—Pravastatin—atherosclerosis	0.000841	0.00205	CcSEcCtD
Rifaximin—Pain—Pravastatin—atherosclerosis	0.000841	0.00205	CcSEcCtD
Rifaximin—Hypersensitivity—Ezetimibe—atherosclerosis	0.00084	0.00205	CcSEcCtD
Rifaximin—Asthenia—Lovastatin—atherosclerosis	0.000834	0.00204	CcSEcCtD
Rifaximin—Pruritus—Lovastatin—atherosclerosis	0.000822	0.00201	CcSEcCtD
Rifaximin—Asthenia—Ezetimibe—atherosclerosis	0.000818	0.002	CcSEcCtD
Rifaximin—Gastrointestinal pain—Niacin—atherosclerosis	0.000816	0.00199	CcSEcCtD
Rifaximin—Nausea—Rosuvastatin—atherosclerosis	0.000815	0.00199	CcSEcCtD
Rifaximin—Feeling abnormal—Pravastatin—atherosclerosis	0.00081	0.00198	CcSEcCtD
Rifaximin—Pruritus—Ezetimibe—atherosclerosis	0.000807	0.00197	CcSEcCtD
Rifaximin—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000804	0.00196	CcSEcCtD
Rifaximin—Hypersensitivity—Simvastatin—atherosclerosis	0.000801	0.00196	CcSEcCtD
Rifaximin—Diarrhoea—Lovastatin—atherosclerosis	0.000795	0.00194	CcSEcCtD
Rifaximin—Urticaria—Niacin—atherosclerosis	0.000793	0.00194	CcSEcCtD
Rifaximin—Body temperature increased—Niacin—atherosclerosis	0.000789	0.00193	CcSEcCtD
Rifaximin—Abdominal pain—Niacin—atherosclerosis	0.000789	0.00193	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—atherosclerosis	0.000785	0.00812	CbGpPWpGaD
Rifaximin—Urticaria—Pravastatin—atherosclerosis	0.000781	0.00191	CcSEcCtD
Rifaximin—Asthenia—Simvastatin—atherosclerosis	0.00078	0.0019	CcSEcCtD
Rifaximin—Diarrhoea—Ezetimibe—atherosclerosis	0.00078	0.0019	CcSEcCtD
Rifaximin—Body temperature increased—Pravastatin—atherosclerosis	0.000777	0.0019	CcSEcCtD
Rifaximin—Abdominal pain—Pravastatin—atherosclerosis	0.000777	0.0019	CcSEcCtD
Rifaximin—Pruritus—Simvastatin—atherosclerosis	0.000769	0.00188	CcSEcCtD
Rifaximin—Dizziness—Lovastatin—atherosclerosis	0.000769	0.00188	CcSEcCtD
Rifaximin—Dizziness—Ezetimibe—atherosclerosis	0.000754	0.00184	CcSEcCtD
Rifaximin—Diarrhoea—Simvastatin—atherosclerosis	0.000744	0.00182	CcSEcCtD
Rifaximin—Vomiting—Lovastatin—atherosclerosis	0.000739	0.0018	CcSEcCtD
Rifaximin—Hypersensitivity—Niacin—atherosclerosis	0.000736	0.0018	CcSEcCtD
Rifaximin—Rash—Lovastatin—atherosclerosis	0.000733	0.00179	CcSEcCtD
Rifaximin—Dermatitis—Lovastatin—atherosclerosis	0.000732	0.00179	CcSEcCtD
Rifaximin—Headache—Lovastatin—atherosclerosis	0.000728	0.00178	CcSEcCtD
Rifaximin—Vomiting—Ezetimibe—atherosclerosis	0.000725	0.00177	CcSEcCtD
Rifaximin—Hypersensitivity—Pravastatin—atherosclerosis	0.000724	0.00177	CcSEcCtD
Rifaximin—Dizziness—Simvastatin—atherosclerosis	0.000719	0.00175	CcSEcCtD
Rifaximin—Rash—Ezetimibe—atherosclerosis	0.000719	0.00175	CcSEcCtD
Rifaximin—Dermatitis—Ezetimibe—atherosclerosis	0.000718	0.00175	CcSEcCtD
Rifaximin—Asthenia—Niacin—atherosclerosis	0.000716	0.00175	CcSEcCtD
Rifaximin—Headache—Ezetimibe—atherosclerosis	0.000714	0.00174	CcSEcCtD
Rifaximin—Pruritus—Niacin—atherosclerosis	0.000706	0.00172	CcSEcCtD
Rifaximin—Asthenia—Pravastatin—atherosclerosis	0.000705	0.00172	CcSEcCtD
Rifaximin—Pruritus—Pravastatin—atherosclerosis	0.000695	0.0017	CcSEcCtD
Rifaximin—Vomiting—Simvastatin—atherosclerosis	0.000691	0.00169	CcSEcCtD
Rifaximin—Nausea—Lovastatin—atherosclerosis	0.00069	0.00169	CcSEcCtD
Rifaximin—Rash—Simvastatin—atherosclerosis	0.000686	0.00167	CcSEcCtD
Rifaximin—Dermatitis—Simvastatin—atherosclerosis	0.000685	0.00167	CcSEcCtD
Rifaximin—Diarrhoea—Niacin—atherosclerosis	0.000683	0.00167	CcSEcCtD
Rifaximin—Headache—Simvastatin—atherosclerosis	0.000681	0.00166	CcSEcCtD
Rifaximin—Nausea—Ezetimibe—atherosclerosis	0.000677	0.00165	CcSEcCtD
Rifaximin—Diarrhoea—Pravastatin—atherosclerosis	0.000673	0.00164	CcSEcCtD
Rifaximin—Dizziness—Niacin—atherosclerosis	0.00066	0.00161	CcSEcCtD
Rifaximin—Dizziness—Pravastatin—atherosclerosis	0.00065	0.00159	CcSEcCtD
Rifaximin—Nausea—Simvastatin—atherosclerosis	0.000646	0.00158	CcSEcCtD
Rifaximin—Vomiting—Niacin—atherosclerosis	0.000635	0.00155	CcSEcCtD
Rifaximin—Rash—Niacin—atherosclerosis	0.000629	0.00154	CcSEcCtD
Rifaximin—Dermatitis—Niacin—atherosclerosis	0.000629	0.00153	CcSEcCtD
Rifaximin—Headache—Niacin—atherosclerosis	0.000625	0.00153	CcSEcCtD
Rifaximin—Vomiting—Pravastatin—atherosclerosis	0.000625	0.00153	CcSEcCtD
Rifaximin—CYP3A4—Estrogen metabolism—GSTM1—atherosclerosis	0.000623	0.00644	CbGpPWpGaD
Rifaximin—Rash—Pravastatin—atherosclerosis	0.00062	0.00151	CcSEcCtD
Rifaximin—Dermatitis—Pravastatin—atherosclerosis	0.000619	0.00151	CcSEcCtD
Rifaximin—Headache—Pravastatin—atherosclerosis	0.000616	0.0015	CcSEcCtD
Rifaximin—Nausea—Niacin—atherosclerosis	0.000593	0.00145	CcSEcCtD
Rifaximin—Nausea—Pravastatin—atherosclerosis	0.000584	0.00143	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7A1—atherosclerosis	0.000576	0.00596	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP7A1—atherosclerosis	0.000568	0.00588	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PARP1—atherosclerosis	0.000553	0.00572	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—atherosclerosis	0.000532	0.00551	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—atherosclerosis	0.000525	0.00543	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR2—atherosclerosis	0.000524	0.00542	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—atherosclerosis	0.000468	0.00485	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP7A1—atherosclerosis	0.000467	0.00483	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—atherosclerosis	0.000431	0.00446	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARA—atherosclerosis	0.00035	0.00363	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atherosclerosis	0.000325	0.00336	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR1—atherosclerosis	0.000317	0.00329	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HSPA1B—atherosclerosis	0.000299	0.00309	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARG—atherosclerosis	0.00029	0.003	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—atherosclerosis	0.000268	0.00278	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PARP1—atherosclerosis	0.000266	0.00275	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—SERPINE1—atherosclerosis	0.000261	0.0027	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ESR2—atherosclerosis	0.000252	0.00261	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP7A1—atherosclerosis	0.000248	0.00256	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP7A1—atherosclerosis	0.000244	0.00253	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP27A1—atherosclerosis	0.000229	0.00237	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP27A1—atherosclerosis	0.000226	0.00234	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SIRT1—atherosclerosis	0.000203	0.0021	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARA—atherosclerosis	0.000169	0.00175	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ESR1—atherosclerosis	0.000153	0.00158	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARG—atherosclerosis	0.000139	0.00144	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SERPINE1—atherosclerosis	0.000126	0.0013	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	0.000102	0.00106	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	0.000101	0.00104	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MAPK3—atherosclerosis	8.17e-05	0.000846	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	7.26e-05	0.000751	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PLTP—atherosclerosis	6.82e-05	0.000706	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LTA4H—atherosclerosis	5.92e-05	0.000612	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCG8—atherosclerosis	5.92e-05	0.000612	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—atherosclerosis	5.51e-05	0.000571	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCG1—atherosclerosis	4.68e-05	0.000484	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LCAT—atherosclerosis	4.4e-05	0.000455	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—FABP4—atherosclerosis	4.4e-05	0.000455	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOA4—atherosclerosis	4.32e-05	0.000447	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP7A1—atherosclerosis	4.24e-05	0.000439	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP27A1—atherosclerosis	3.92e-05	0.000405	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	3.71e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOA2—atherosclerosis	3.71e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	3.71e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALOX15—atherosclerosis	3.71e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCG5—atherosclerosis	3.67e-05	0.00038	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LPA—atherosclerosis	3.54e-05	0.000367	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—BGN—atherosclerosis	3.43e-05	0.000355	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOA5—atherosclerosis	3.4e-05	0.000352	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	3.27e-05	0.000338	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALOX5—atherosclerosis	3.16e-05	0.000327	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.83e-05	0.000293	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LIPC—atherosclerosis	2.82e-05	0.000291	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOC3—atherosclerosis	2.8e-05	0.000289	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LDLR—atherosclerosis	2.78e-05	0.000288	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CETP—atherosclerosis	2.72e-05	0.000281	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.6e-05	0.000269	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.46e-05	0.000254	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.19e-05	0.000227	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.88e-05	0.000194	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOB—atherosclerosis	1.8e-05	0.000186	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.75e-05	0.000181	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LPL—atherosclerosis	1.72e-05	0.000178	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GPX1—atherosclerosis	1.68e-05	0.000173	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CD36—atherosclerosis	1.63e-05	0.000169	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.55e-05	0.00016	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARA—atherosclerosis	1.52e-05	0.000157	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AGT—atherosclerosis	1.47e-05	0.000152	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOE—atherosclerosis	1.44e-05	0.000149	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CAV1—atherosclerosis	1.43e-05	0.000148	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOA1—atherosclerosis	1.42e-05	0.000147	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.3e-05	0.000134	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARG—atherosclerosis	1.25e-05	0.00013	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—INS—atherosclerosis	1.23e-05	0.000127	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALB—atherosclerosis	1.13e-05	0.000117	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NOS3—atherosclerosis	1.08e-05	0.000112	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTGS2—atherosclerosis	9.87e-06	0.000102	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—atherosclerosis	4.96e-06	5.13e-05	CbGpPWpGaD
